These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32213921)

  • 1. Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment.
    Goldsberry WN; Meza-Perez S; Londoño AI; Katre AA; Mott BT; Roane BM; Goel N; Wall JA; Cooper SJ; Norian LA; Randall TD; Birrer MJ; Arend RC
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32213921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
    Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.
    Doo DW; Meza-Perez S; Londoño AI; Goldsberry WN; Katre AA; Boone JD; Moore DJ; Hudson CT; Betella I; McCaw TR; Gangrade A; Bao R; Luke JJ; Yang ES; Birrer MJ; Starenki D; Cooper SJ; Buchsbaum DJ; Norian LA; Randall TD; Arend RC
    Ther Adv Med Oncol; 2020; 12():1758835920913798. PubMed ID: 32313567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.
    Dholakia J; Scalise CB; Katre AA; Goldsberry WN; Meza-Perez S; Randall TD; Norian LA; Novak L; Arend RC
    Gynecol Oncol; 2022 Jan; 164(1):170-180. PubMed ID: 34844776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
    Li X; Xiang Y; Li F; Yin C; Li B; Ke X
    Front Immunol; 2019; 10():2293. PubMed ID: 31616443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations.
    Aoki T; Nishida N; Kurebayashi Y; Sakai K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Ueshima K; Minami Y; Tsurusaki M; Nakai T; Sakamoto M; Nishio K; Kudo M
    Liver Cancer; 2024 Jun; 13(3):285-305. PubMed ID: 38894812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Wnt/β-catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity.
    Pundkar C; Antony F; Kang X; Mishra A; Babu RJ; Chen P; Li F; Suryawanshi A
    Heliyon; 2023 Jun; 9(6):e16688. PubMed ID: 37313143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel porcupine inhibitor blocks WNT pathways and attenuates cardiac hypertrophy.
    Jiang J; Lan C; Li L; Yang D; Xia X; Liao Q; Fu W; Chen X; An S; Wang WE; Zeng C
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3459-3467. PubMed ID: 30076960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
    Betella I; Turbitt WJ; Szul T; Wu B; Martinez A; Katre A; Wall JA; Norian L; Birrer MJ; Arend R
    Gynecol Oncol; 2020 Jun; 157(3):765-774. PubMed ID: 32192732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
    Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
    Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
    Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
    Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt/β-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis.
    Nguyen VHL; Hough R; Bernaudo S; Peng C
    J Ovarian Res; 2019 Dec; 12(1):122. PubMed ID: 31829231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
    Zhang C; Zhang Z; Zhang S; Wang W; Hu P
    Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual pocket binding novel tankyrase inhibitor K-476 enhances the efficacy of immune checkpoint inhibitor by attracting CD8
    Kinosada H; Okada-Iwasaki R; Kunieda K; Suzuki-Imaizumi M; Takahashi Y; Miyagi H; Suzuki M; Motosawa K; Watanabe M; Mie M; Ishii T; Ishida H; Saito JI; Nakai R
    Am J Cancer Res; 2021; 11(1):264-276. PubMed ID: 33520373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.
    Wu G; Liu A; Zhu J; Lei F; Wu S; Zhang X; Ye L; Cao L; He S
    Oncotarget; 2015 Oct; 6(30):28882-94. PubMed ID: 26337084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers.
    Yang Q; Qin T; An T; Wu H; Xu G; Xiang J; Lei K; Zhang S; Xia J; Su G; Wang D; Xue M; Kong L; Zhang W; Wu S; Li Y
    Eur J Pharmacol; 2023 Apr; 945():175628. PubMed ID: 36858339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of R-spondin 1 through activating Wnt/β-catenin in the growth, survival and migration of ovarian cancer cells.
    Liu Q; Zhao Y; Xing H; Li L; Li R; Dai J; Li Q; Fang S
    Gene; 2019 Mar; 689():124-130. PubMed ID: 30572097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.